Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694617 | 1.00 | ALDH1A1 (0.52) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| SCHEMBL28228323 | 1.00 | ALDH1A1 (0.52) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10811290 | 0.98 | ALDH1A1 (0.50) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| SCHEMBL11374500 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| SCHEMBL9364482 | 0.82 | LMNA (0.44) | ALDH1A1LMNASMN1; SMN2HTTMEN1 | |
| Hydroxylated Completely Delakylated Diethylpropion SCHEMBL5319402 | 0.82 | CA1 (0.50) | LMNACES2HTTPKMHPGD | |
| Hydroxylated Completely Delakylated Diethylpropion SCHEMBL27460979 | 0.82 | CA1 (0.50) | LMNACES2HTTPKMHPGD | |
| SCHEMBL585256 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| SCHEMBL10577256 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNACES2CES1SMN1; SMN2 | |
| Hydroxylated Completely Delakylated Diethylpropion SCHEMBL5172799 | 0.80 | CA1 (0.48) | LMNACES2HTTPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385172-B1 | MULTICAST-BROADCAST USER SERVICE ARCHITECTURE | QUALCOMM INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-12369012-B2 | Multicast-broadcast user service architecture | QUALCOMM INCORPORATED (US) | 2025-07-22 | — | — | US | claimed |
| WO-2025092300-A1 | USE OF ADRENORECEPTOR AGONISTS IN PROMOTING HEMATOPOIETIC REGENERATION | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2025-05-08 | — | — | WO | claimed |
| CN-119898819-A | V-W inorganic porous material, preparation method and application thereof | 南京师范大学 | 2025-04-29 | — | — | CN | claimed |
| WO-2025078657-A1 | AMPLIFICATION-FREE TARGET ENRICHMENT WORKFLOW FOR DIRECT DETECTION OF NUCLEIC ACID MODIFICATIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-17 | — | — | WO | claimed |
| EP-4385172-A1 | MULTICAST-BROADCAST USER SERVICE ARCHITECTURE | QUALCOMM INCORPORATED (US) | 2024-06-19 | — | — | EP | claimed |
| CN-117795907-A | Multicast-broadcast user service architecture | 高通股份有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3694900-B1 | NON-AQUEOUS CROSSLINKABLE COMPOSITION | ALLNEX NETHERLANDS BV (NL) | 2024-01-24 | — | — | EP | claimed |
| CN-113083276-B | Titanium dioxide/zinc oxide heterojunction material with dendritic structure and preparation method thereof | 浙江理工大学 | 2023-02-28 | — | — | CN | claimed |
| WO-2023019061-A1 | MULTICAST-BROADCAST USER SERVICE ARCHITECTURE | QUALCOMM INCORPORATED (US) | 2023-02-16 | — | — | WO | claimed |
| US-20230052505-A1 | MULTICAST-BROADCAST USER SERVICE ARCHITECTURE | QUALCOMM INCORPORATED | 2023-02-16 | — | — | US | claimed |
| US-11572431-B2 | Non-aqueous crosslinkable composition | ALLNEX NETHERLANDS B.V. (NL) | 2023-02-07 | — | — | US | claimed |
| EP-3941957-A1 | NON-AQUEOUS CROSSLINKABLE COMPOSITION | Allnex Netherlands B.V. (NL) | 2022-01-26 | — | — | EP | claimed |
| WO-2026107065-A1 | ANALYSIS OF NUCLEIC ACIDS FROM PRESERVED SAMPLES | DOVETAIL GENOMICS, LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122005616-A | Preparation method and application of roxburgh rose polysaccharide-mucin-philic Ackermans mixture | 贵州中医药大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125739-A1 | GENERATION OF PHASED READ-SETS FOR GENOME ASSEMBLY AND HAPLOTYPE PHASING | DOVETAIL GENOMICS LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-5552557-A | Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0471358-B1 | Fluoroethylcamptothecin derivatives | KYORIN SEIYAKU KK (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0653421-A1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| EP-0471358-A1 | Fluoroethylcamptothecin derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125739-A1 | GENERATION OF PHASED READ-SETS FOR GENOME ASSEMBLY AND HAPLOTYPE PHASING | SMCHD1, SMC2, SMC1A | ALDH1A1 4720/4885LMNA 269/4885CES2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.